Cytek Biosciences, Inc.CTKBNASDAQ
Loading
Operating Income Growth AcceleratingAccelerating
Percentile Rank65
5Y CAGR+17.7%
Year-over-Year Change
Year-over-year operating income growth rate
5Y CAGR
+17.7%/yr
Long-term compound
Percentile
P65
Within normal range
vs 5Y Ago
2.3x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 39.14% |
| Q3 2025 | 13.48% |
| Q2 2025 | 29.06% |
| Q1 2025 | -601.51% |
| Q4 2024 | 170.29% |
| Q3 2024 | 50.18% |
| Q2 2024 | 20.56% |
| Q1 2024 | -7735.04% |
| Q4 2023 | 97.87% |
| Q3 2023 | 29.66% |
| Q2 2023 | 24.95% |
| Q1 2023 | -14578.57% |
| Q4 2022 | -93.82% |
| Q3 2022 | 252.64% |
| Q2 2022 | 62.20% |
| Q1 2022 | -278.97% |
| Q4 2021 | -54.54% |
| Q3 2021 | -23.98% |
| Q2 2021 | 236.66% |
| Q1 2021 | -85.63% |
| Q4 2020 | 17.36% |
| Q3 2020 | 3178.44% |
| Q2 2020 | 69.30% |
| Q1 2020 | 0.00% |